PHARMAZEUTISCHE FORMULIERUNGEN

European patent · EP4527467 · In force

Register entry

Publication number
EP4527467
Application number
EP24216441
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jun 29, 2016
Published
Mar 26, 2025
Granted
Mar 18, 2026
Protection ends at the latest
Jun 28, 2036
Next annual fee due
Jun 30, 2027
IPC classes
A61K 9/20 (2006.01)
A61K 9/24 (2006.01)
A61K 31/513 (2006.01)
A61K 31/675 (2006.01)
A61K 9/00 (2006.01)
A61K 9/28 (2006.01)
A61P 43/00 (2006.01)
A61P 31/18 (2006.01)
Priority
US 201562187113 P 30.06.2015
US 201662298373 P 22.02.2016
US 201662301429 P 29.02.2016
US 201662317286 P 01.04.2016
Divided from
EP23162978
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jul 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.06.2026 → 30.06.2027

    Published in Swissreg on 01.07.2026

  2. Apr 15, 2026

    Agent entered

    Representative
    E. Blum & Co. AG, Hofwiesenstrasse 349, 8050 Zürich

    Published in Swissreg on 15.04.2026

  3. Mar 18, 2026

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 18.03.2026

Parties

Holder

Gilead Sciences, Inc.

333 Lakeside Drive, Foster City, CA 94404, US

Agent

E. Blum & Co. AG

Hofwiesenstrasse 349, 8050 Zürich

Inventor

KOZIARA, Joanna, M.

Foster City, 94404, US

MCCALLISTER, Scott

Foster City, 94404, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.